KRRO vs WVE
KRRO: Korro Bio is a clinical-stage genetic medicine company using its proprietary OPERA platform to develop precise, transient RNA-editing therapies for rare and complex diseases. WVE: Wave Life Sciences is a clinical-stage biotech company developing stereopure nucleic acid therapeutics via its proprietary PRISM platform to treat genetically defined diseases.
Side-by-side fundamentals
| Metric | KRRO | WVE | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $9.44 | $3.42 | |
| Market cap | $139M | $674M | |
| Net margin FY2025, SEC XBRL | -1834.5% | -478.3% | WVE higher |
| Operating margin FY2025, SEC XBRL | -1906.4% | -504.1% | WVE higher |
| ROE FY2025, SEC XBRL | -228.0% | -39.4% | WVE higher |
| ROA FY2025, SEC XBRL | -103.3% | -32.0% | WVE higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +181.5% | -60.5% | KRRO higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +127.1% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.79 | 1.46 | |
| 1-year return as of 2026-10-20 close | -79.6% | -56.2% | WVE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.